Skip to main content

International Psoriasis Council

International Psoriasis Council
subscribe
6   What's New
Search
subscribe
Search

Advancing Knowledge. Improving Care.

Matthew

Vesely

,

MD, PhD

Assistant Professor
Yale University
New Haven
,
Connecticut
,
United States
2021 Fellow
IPC Jr. Councilor
Request an Update
Dr. Matthew Vesely is an Assistant Professor of Dermatology at Yale School of Medicine. He is a physician-scientist focusing on inflammatory skin diseases, including psoriasis, cutaneous lupus, and lichen planus. Dr. Vesely leads a basic and translational immunology research program investigating immune resolution pathways in the skin. His work focuses on the role of immune checkpoint receptors and vascular dysfunction in chronic inflammation. His group explores immune checkpoint agonism and endothelial normalization as potential therapeutic strategies in psoriasis and related conditions. Dr. Vesely earned his MD and PhD degrees from Washington University in St. Louis and completed his dermatology residency at Yale. He was named an IPC Fellow in 2021 under the mentorship of Dr. Alice Gottlieb. In 2025, he received a Discovery Grant from the National Psoriasis Foundation (NPF).
Last Updated:
07/06/2025

Areas of Interest

Development of Psoriatic Arthritis, Novel Drug Discovery

Languages Spoken

English

Involvement with Other Organization(s)

Membership Committee in Society for Investigative Dermatology; Treasurer for New England Dermatology Society
Recent publications

Featured

Page

Managing Psoriasis in Patients with Cancer: Evidence and Expert Guidance from Professor Caitriona Ryan.

Expert dermatologist Professor Ryan discusses the link between psoriasis and malignancy, treatment safety, and best…

View Report

Page

Malignancy in Psoriasis.

In this IPC Expert Insights article, Dr. Matthew Vesely examines cancer risk in psoriasis and provides insights on…

View Report

Blog

Shining a Spotlight: Catching up with 2021 IPC Fellow Matthew Vesely, MD, PhD.

In this interview, we catch up with Dr. Matthew Vesely, a 2021 IPC Fellow. He shares insights on his journey since…

Read More

Video

Challenging Case 3: A Patient with Active Cancer.

Dr. Vesely presents a challenging case featuring a patient with active cancer.

Watch Video

Blog

Focus on Psoriasis: A Report from the 2023 American Academy of Dermatology (AAD) Annual Meeting.

The 2023 American Academy of Dermatology (AAD) Annual Meeting was held Thursday, March 16 – Tuesday, March 21, 2023,…

Read More

PDF

Focus on Psoriasis: A Report from the 2023 American Academy of Dermatology (AAD) Annual Meeting.

The 2023 American Academy of Dermatology (AAD) Annual Meeting was held Thursday, March 16 – Tuesday, March 21, 2023,…

View Report

Event

Symposium: Psoriasis: Using the Right Treatment in the Right Patient at the Right Time.

AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING (AAD) | NEW ORLEANS, LA Thursday, March 16 14:00 - 17:00…

March 16, 2023
Learn More or Register

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026